Stericycle (NASDAQ:SRCL) Updates FY 2024 Earnings Guidance

Stericycle (NASDAQ:SRCL) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.200-2.500 for the period, compared to the consensus earnings per share estimate of 2.330. The company issued revenue guidance of -.

Stericycle Price Performance

Shares of Stericycle stock traded down $0.20 on Friday, hitting $46.31. The company had a trading volume of 802,019 shares, compared to its average volume of 467,025. The business has a 50-day simple moving average of $51.35 and a 200-day simple moving average of $48.17. The company has a debt-to-equity ratio of 0.51, a current ratio of 0.94 and a quick ratio of 0.94. The company has a market cap of $4.30 billion, a PE ratio of -192.95, a PEG ratio of 2.68 and a beta of 1.09. Stericycle has a 52 week low of $37.78 and a 52 week high of $57.06.

Stericycle (NASDAQ:SRCL) last posted its quarterly earnings data on Thursday, April 25th. The business services provider reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.54 by $0.03. The business had revenue of $664.90 million during the quarter, compared to analysts’ expectations of $676.42 million. Stericycle had a negative net margin of 0.80% and a positive return on equity of 7.06%. The business’s revenue was down 2.8% on a year-over-year basis. During the same period last year, the firm posted $0.49 earnings per share. Research analysts expect that Stericycle will post 2.32 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SRCL. Wells Fargo & Company increased their target price on shares of Stericycle from $40.00 to $48.00 and gave the company an underweight rating in a research note on Friday, March 1st. Royal Bank of Canada restated an outperform rating and issued a $69.00 price target on shares of Stericycle in a research report on Thursday, March 7th. StockNews.com downgraded shares of Stericycle from a buy rating to a hold rating in a research report on Tuesday, April 2nd. Robert W. Baird reduced their price target on shares of Stericycle from $62.00 to $55.00 and set a neutral rating for the company in a research report on Friday. Finally, Truist Financial upped their price target on shares of Stericycle from $50.00 to $57.00 and gave the company a hold rating in a research report on Thursday, February 29th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Stericycle currently has a consensus rating of Hold and a consensus price target of $60.80.

Stericycle Company Profile

Stericycle, Inc, together with its subsidiaries, provides regulated waste and compliance services in the United States, Europe, and internationally. The company offers regulated waste and compliance services, including regulated medical waste, sharps waste management and disposal, pharmaceutical waste management and disposal, chemotherapy waste and disposal, controlled substance waste disposal, healthcare hazardous waste, and integrated waste stream solutions; specialty services, such as MedDrop medication collection kiosks, safe community solutions, SafeDrop sharps mailback solutions, and airport and maritime waste services; medical supply store services, that includes sharps and disposable biohazardous waste containers, infection control supplies, and seal&send medication mail back; and compliance solutions including Steri-Safe compliance solutions.